Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020110974 - THERAPEUTIC AND PROPHYLACTIC METHOD FOR TUMOR TREATABLE WITH ENDOCRINE THERAPY BY COMBINED USE OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR WITH ENDOCRINE THERAPY

Publication Number WO/2020/110974
Publication Date 04.06.2020
International Application No. PCT/JP2019/045901
International Filing Date 25.11.2019
IPC
A61K 31/138 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/519 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/565 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 45/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
CPC
A61K 31/138
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 31/565
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applicants
  • 大鵬薬品工業株式会社 TAIHO PHARMACEUTICAL CO., LTD. [JP]/[JP]
Inventors
  • 平井 洋 HIRAI, Hiroshi
  • 三浦 晃敬 MIURA, Akihiro
  • 五月女 裕 SOOTOME, Hiroshi
Agents
  • 特許業務法人三枝国際特許事務所 SAEGUSA & PARTNERS
Priority Data
2018-22004626.11.2018JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) THERAPEUTIC AND PROPHYLACTIC METHOD FOR TUMOR TREATABLE WITH ENDOCRINE THERAPY BY COMBINED USE OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR WITH ENDOCRINE THERAPY
(FR) PROCÉDÉ THÉRAPEUTIQUE ET PROPHYLACTIQUE CONTRE UNE TUMEUR POUVANT ÊTRE TRAITÉE PAR ENDOCRINOTHÉRAPIE FAISANT APPEL À UNE UTILISATION COMBINÉE D'UN INHIBITEUR DES RÉCEPTEURS DU FACTEUR DE CROISSANCE DES FIBROBLASTES ET D'UNE ENDOCRINOTHÉRAPIE
(JA) 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法
Abstract
(EN)
Provided is a novel therapeutic method for a cancerous tumor treatable with endocrine therapy, said method comprising using an FGFR inhibitor (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-on or a pharmaceutically acceptable salt thereof. Also provided are a pharmaceutical composition for treating and/or preventing a tumor treatable with endocrine therapy, said composition comprising the aforesaid compound or a pharmaceutically acceptable salt thereof, characterized by being to be used in combination with endocrine therapy, as well as a compound, a use, a method and a combination each relating thereto.
(FR)
L'invention concerne un nouveau procédé thérapeutique contre une tumeur cancéreuse pouvant être traitée par endocrinothérapie, ledit procédé comprenant l'utilisation d'un inhibiteur des FGFR, la (S)-1-(3-(4-amino-3-((3,5-diméthoxyphényl))éthynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-én-1-one ou d'un sel de qualité pharmaceutique de celle-ci. L'invention concerne également une composition pharmaceutique pour le traitement et/ou la prévention d'une tumeur pouvant être traitée par endocrinothérapie, ladite composition comprenant le composé mentionné ci-dessus ou un sel de qualité pharmaceutique de celui-ci, caractérisée en ce qu'elle est destinée à être utilisée en combinaison avec une endocrinothérapie, ainsi qu'un composé, une utilisation, un procédé et une combinaison associés.
(JA)
FGFR阻害剤(S)-1-(3-(4-アミノ-3-((3,5-ジメトキシフェニル)エチニル)-1H-ピラゾロ[3,4-d]ピリミジン-1-イル)ピロリジン-1-イル)プロパ-2-エン-1-オン又はその薬学的に許容される塩を用いた、内分泌療法が適用される癌腫瘍の新規な治療方法を提供する。さらに、内分泌療法と併用することを特徴とする、内分泌療法が適用される腫瘍の治療及び/又は予防のための前記化合物又はその薬学的に許容される塩を含有する医薬組成物、並びに関連する化合物、使用、方法、組み合わせを提供する。
Latest bibliographic data on file with the International Bureau